Arcturus Therapeutics Holdings Inc. Stock
Equities
ARCT
US03969T1097
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
31.21 USD | -3.61% | +2.33% | -1.01% |
Financials (USD)
Sales 2024 * | 182M | Sales 2025 * | 229M | Capitalization | 841M |
---|---|---|---|---|---|
Net income 2024 * | -81M | Net income 2025 * | -47M | EV / Sales 2024 * | 2.77 x |
Net cash position 2024 * | 336M | Net cash position 2025 * | - | EV / Sales 2025 * | 3.67 x |
P/E ratio 2024 * |
-10.4
x | P/E ratio 2025 * |
-20.2
x | Employees | 180 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.25% |
Latest transcript on Arcturus Therapeutics Holdings Inc.
1 day | -3.61% | ||
1 week | +2.33% | ||
Current month | +22.06% | ||
1 month | +11.74% | ||
3 months | -16.60% | ||
6 months | +32.64% | ||
Current year | -1.01% |
Managers | Title | Age | Since |
---|---|---|---|
Joseph Payne
CEO | Chief Executive Officer | 52 | 13-02-28 |
Andrew Sassine
DFI | Director of Finance/CFO | 59 | 18-12-31 |
Chief Operating Officer | 45 | 12-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Edward Holmes
BRD | Director/Board Member | 83 | 19-08-31 |
James Barlow
BRD | Director/Board Member | 65 | 18-05-26 |
Peter Farrell
CHM | Chairman | 81 | 18-05-26 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 31.21 | -3.61% | 600,634 |
24-05-22 | 32.38 | +8.48% | 659,654 |
24-05-21 | 29.85 | -2.13% | 244,549 |
24-05-20 | 30.5 | +2.42% | 311,913 |
24-05-17 | 29.78 | -2.36% | 354,617 |
Delayed Quote Nasdaq, May 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.01% | 872M | |
+64.92% | 62.59B | |
-1.85% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+13.05% | 26.21B | |
-21.96% | 19.09B | |
+4.21% | 13.08B | |
+25.74% | 12.26B | |
+27.42% | 12.05B |
- Stock Market
- Equities
- ARCT Stock